NovaBridge Biosciences (FRA:0VY) ROA %: -45.84% (As of Dec. 2025)


FRA:0VY NovaBridge Biosciences FRA:0VY
24 GF Score
Price €1.71
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences ROA %?

NovaBridge Biosciences FRA:0VY +20.42% 24 ROA % is -45.84% as of Dec. 2025. GuruFocus rates FRA:0VY with a GF Score™ of 24/100 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,418 Biotechnology companies, NovaBridge Biosciences ranks better than 60.58% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. NovaBridge Biosciences's annualized Net Income for the quarter that ended in Dec. 2025 was €-105.17 Mil. NovaBridge Biosciences's average Total Assets over the quarter that ended in Dec. 2025 was €229.42 Mil. Therefore, NovaBridge Biosciences's annualized ROA % for the quarter that ended in Dec. 2025 was -45.84%.

The historical rank and industry rank for NovaBridge Biosciences's ROA % or its related term are showing as below:

FRA:0VY' s ROA % Range Over the Past 10 Years
Min: -69.9   Med: -29.09   Max: 11.84
Current: -19.84

During the past 9 years, NovaBridge Biosciences's highest ROA % was 11.84%. The lowest was -69.90%. And the median was -29.09%.

FRA:0VY's ROA % is ranked better than
60.58% of 1418 companies
in the Biotechnology industry
Industry Median: -32.87 vs FRA:0VY: -19.84

NovaBridge Biosciences  (FRA:0VY) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-105.168/229.4195
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-105.168 / 0)*(0 / 229.4195)
=Net Margin %*Asset Turnover
=N/A %*0
=-45.84 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


NovaBridge Biosciences ROA % Related Terms


NovaBridge Biosciences ROA % Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences ROA % Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial Premium Member Only -41.12 -52.47 -42.53 -7.84 -18.57

NovaBridge Biosciences Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.07 -5.88 -10.25 -11.20 -45.84

FRA:0VY vs HUMA, DTIL, ORMP: ROA % Comparison

For the Biotechnology subindustry, NovaBridge Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovaBridge Biosciences ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where NovaBridge Biosciences's ROA % falls into.


FRA:0VY
24GF Score
NovaBridge Biosciences FRA:0VY
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences ROA % Calculation

NovaBridge Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-39.514/( (203.109+222.486)/ 2 )
=-39.514/212.7975
=-18.57 %

NovaBridge Biosciences's annualized ROA % for the quarter that ended in Dec. 2025 is calculated as:

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-105.168/( (236.353+222.486)/ 2 )
=-105.168/229.4195
=-45.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2025) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -45.84% mean?
NovaBridge Biosciences (FRA:0VY) has a ROA % of -45.84% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on NovaBridge Biosciences and its competitors. According to the industry distribution chart, NovaBridge Biosciences ranks #559 out of 1418 companies in the Biotechnology industry, placing it in the top 39.4%.
Is NovaBridge Biosciences' ROA % too high?
NovaBridge Biosciences' current ROA % is -45.84%. Based on the distribution chart, NovaBridge Biosciences ranks #559 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NovaBridge Biosciences has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' ROA % compare to HUMA and DTIL?
According to the Biotechnology industry distribution chart, NovaBridge Biosciences ranks #559 out of 1418 companies for ROA %. This puts NovaBridge Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current ROA % is -45.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
Based on GuruFocus' analysis, NovaBridge Biosciences (FRA:0VY) is currently considered Possible Value Trap. The current ROA % is -45.84%. NovaBridge Biosciences' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current ROA % is -45.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
24GF Score

Get the complete analysis for FRA:0VY

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.71
Price